Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2008

View Archived Issues

Wetimicin studied in phase I in China as new broad-spectrum antibiotic

New preclinical data demonstrate antidepressant activity of ITI-007

Aradigm initiates clinical trial of Lung Rx's inhaled treprostinil using AERx Essence

Schering-Plough terminates collaboration agreement with Novacea for Asentar

CuraGen advances CR011-vcMMAE into phase II for advanced melanoma

Futura Medical updates progress on development of TPR-100 using DermaSys

Glucose-lowering activity of Merck's novel glucagon receptor antagonist shown in vivo

Pfizer's novel 5-HT1B inverse agonist shows antidepressant activity in vivo

In vivo cognitive enhancement by WAY-101, a novel 5-HT6 antagonist

Novel agents for cardiovascular disorders disclosed in recent patent

New wound-healing agents described in recent Hokkaido University and Shionogi patent

New immunosuppressants reported in recent patent literature

ImClone Systems initiates phase II clinical trial of IMC-A12 in head and neck cancer

Lorus signs exclusive multinational license agreement with Zoticon for Virulizin

FDA grants orphan drug designation to Kamada's aerosolized AAT for bronchiectasis

Immunomedics reports results from phase I/II study of veltuzumab

Barrier Therapeutics reports positive results from phase II study of oral antihistamine Hivenyl

FDA grants fast track designation to Neopharm's NPL-2008 in autism disorder

Recombinant butyrylcholinesterase may play a neuroprotective role in AD

FDA accepts oritavancin NDA for standard review

Potentia completes round of financing to advance POT-4 clinical program in AMD

Abilify granted EU marketing authorization for manic episodes in bipolar I

Amrubicin designated EMEA orphan medicinal product for small cell lung cancer

Alimta approved for histologically based use in non-small cell lung cancer

Sustained release of platinum species seen with NC-6004 in cancer patients

Clinical responses seen with AME-133v in phase I/II study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...